osis may, at least in part, be due to suppression of IFN-y release.
criteria demonstrated that it was almost entirely IFN'y. This spontaneous release of IFN'y appeared to be compartmentalized to the lung of these patients in that their blood mononuclear cells spontaneously released little or no IFN'y (P < 0.02, compared to sarcoidosis lung mononuclear cells) and no IFNy was detected in their serum. Both lung T lymphocytes and alveolar macrophages contributed to the spontaneous release of IFN-y by lung mononuclear cells from sarcoid patients; purified preparations of T lymphocytes and alveolar macrophages from these patients spontaneously released similar amounts of IFNy (56±21 and 32±11 U/106 cells per 24 h, respectively, P > 0.3). At least one role for IFNy in the pathogenesis of sarcoidosis appeared to be related to activation of alveolar macrophages, as alveolar macrophages recovered from patients with active disease spontaneously killed V3Hluridine-labeled tumor cell targets (17.7±4.5% cytotoxicity compared with 2.8±0.9% in normals, P < 0.02) and purified IFN'y enhanced the ability of alveolar macrophages from sarcoidosis patients with inactive disease to kill similar targets (P < 0.001, compared to alveolar macrophages cultured in medium alone). Treatment of sarcoid patients with corticosteroids, a therapy known to suppress the activity of the disease, caused a marked reduction in the level of spontaneous IFNy release by lung mononuclear cells compared with untreated patients (P < 0.02), which suggests that the effectiveness of corticosteroid therapy in controlling active pulmonary sarcoid-
Introduction
Human gamma interferon (IFNy)' is produced by immune effector cells in response to a variety of stimuli (1) . Although IFN'y is defined as an interferon by virtue of its ability to inhibit viral growth, it is thought to play a major role in intensifying immune processes by virtue of its ability to enhance a variety of macrophage and lymphocyte actions. For example, in human mononuclear phagocytes, IFNy induces the expression of DR-determinants (2, 3) , enhances the presentation of antigens to lymphocytes (4) , and activates blood mononuclear phagocytes to kill tumor cell targets (5) and intracellular parasites (6) . In addition, IFN-y has been shown to enhance a variety of lymphocyte functions, including the stimulation of the expression of interleukin-2 (IL-2) receptors on T lymphocytes (7) , enhancement of natural killer cell activity (8) , inhibition of suppressor T lymphocyte function (9) , and induction of the expression of DR-determinants on the surface of B lymphocytes (10) . In view of this broad-based range of activities, it is logical to conceptualize IFNy as a multipurpose mediator that mononuclear phagocytes and lymphocytes use to up-regulate immune and inflammatory processes.
While the availability of such a mediator provides mononuclear cells with a common means of responding to immune and inflammatory stimuli, the existence of such mediators could be dangerous if their release were exaggerated and/or uncontrolled. Since IFNy stimulates immune and inflammatory cells, failure to regulate its release could logically result in a sustained, heightened cellular immune process that could damage normal tissues.
Sarcoidosis may be an example of such a situation. It is a multisystem disorder characterized by exuberant, apparently uncontrolled cellular immune activity in affected organs (1 1) . In this context, in active pulmonary sarcoidosis, lung T lymphocytes are spontaneously releasing monocyte chemotactic factor (12) and IL-2 (13, 14) and provide nonspecific polyclonal help to B cells (15). Further, lung lymphocytes from patients with active sarcoidosis demonstrate exaggerated natural killer cell activity (16) , an observation consistent with heightened local immune processes. Mononuclear phagocytes from the lung of sarcoid patients also appear activated, in that they demonstrate an enhanced ability to present antigen to autologous T lymphocytes (17) and are spontaneously releasing fibronectin (18) and the alveolar macrophage-derived growth 1. Abbreviations used in this paper: HTLV-1, human T cell lymphoma virus; IFNa, IFN#, and IFNy, alpha, beta, and gamma interferon, respectively; IL-2, interleukin-2; PHA, phytohemagglutinin; SRBC, sheep erythrocyte(s). factor (19) , which are mediators that stimulate fibroblasts to replicate and thus promote the formation of fibrous tissue. Further, patients with active pulmonary sarcoidosis have positive gallium-67 scans (20) , a finding thought to result, at least in part, from the enhanced uptake of gallium-67 by activated alveolar macrophages (21). Strikingly, all of these exaggerated inflammatory and immune processes in pulmonary sarcoid appear compartmentalized such that they are manifest in the lung but not in the blood.
With this background, it is reasonable to hypothesize that lung, but not blood, mononuclear cells recovered from patients with active sarcoidosis are releasing substantial amounts of IFNy. This would not only help to explain some of the exaggerated localized immune processes in sarpoidosis, but also identify a specific process that might be vulnerable to therapeutic attack, resulting in suppression of the disorder.
To for 30 min at 370C, and then eluted at 2 ml/min using warm (370C) medium (26) . The (29) , was concentrated 100-fold using a minicon B-15 macrosolute concentrator (membrane rejection 15,000 mol wt, Amicon Corp., Danvers, MA) so that the concentration of macromolecules of molecular weight >15,000 was restored to its approximate in vivo value. Serum and epithelial lining fluid were then evaluated for IFNy activity as described above. To determine if serum of epithelial lining fluid contained inhibitors of IFN-y activity, a standard preparation of IFNy was added to these samples then assayed for IFNy.
Evaluation of macrophage activation. Activation of alveolar macrophages from normal volunteers and nonsmoking patients with sarcoidosis was assessed by measuring their capacity to spontaneously kill labeled tumor cell targets in a 72-h assay (30) To determine if IFN'y could stimulate the alveolar macrophages from sarcoidosis patients with inactive disease to express a level of activation similar to that seen in alveolar macrophages from patients with active disease, purified IFN-y (Interferon Sciences, 250 U/ml) was added to cultures of alveolar macrophages (obtained as above) from nonsmoking patients with inactive sarcoidosis. After incubation for 24 h at 37°C, the cells were washed twice and then evaluated for cytotoxicity against the A375 melanoma target over 72 h as above, and compared with the cytotoxicity seen in alveolar macrophages incubated in medium alone or in the presence of lipopolysaccharide (Difco Laboratories, Detroit, MI; 10 tg/ml), a known alveolar macrophage-activating agent (30) . In all experiments, background release was determined by culturing target cells in medium alone (control wells) and was routinely .25% of total dpm over the 72-h period. To terminate the assay, the supernatant was aspirated and the cell layer lysed using 0.1 N NaOH. The samples were counted and a cytotoxicity index (percentage) calculated as (supernatant counts in test wells -supernatant counts in control wells) X (100/total counts per well).
Effect ofcorticosteroid therapy on lung mononuclear cell release of gamma interferon. To evaluate the effect of corticosteroid therapy on the spontaneous release of IFN-y by lung mononuclear cells from patients with sarcoidosis, IFN'y release was evaluated before therapy was begun and then reassessed 2.3±0.7 mo after the commencement of therapy. A standard therapy protocol was used (prednisone, I mg/ kg per d for I mo followed by a 5-mg reduction in the daily dose every 10 d), so that at the time of follow-up testing all patients were receiving at least 30 mg prednisone daily. As a control, spontaneous IFN-y release in untreated sarcoidosis patients was measured at two intervals separated by 2.9±0.4 mo. The decision as to whether the patients were to be treated was based on clinical criteria of disease activity without knowledge of the initial IFN'y production level.
Results
Release ofIFNy by normal lung and blood mononuclear cells. Lung mononuclear cells from normal individuals did not spontaneously release detectable interferon (Fig. 1 A) (Fig. 1 B) . However, when stimulated with PHA, these cells released interferon (194±38 U/106 cells per 24 h). With equivalent amounts of mitogen, the absolute level (per 106 mononuclear cells) of interferon release by lung and blood mononuclear cells were similar (P > 0.2).
Characterization of the interferon released by the PHAstimulated normal lung mononuclear cells demonstrated that: (1) it did not inhibit viral lysis of bovine cells but did inhibit viral lysis of human WISH cells; (2) it lost activity by incubation at pH 2; and (3) it was inhibited by an antibody to IFNy, but not to alpha or beta interferon (Table I) . Together, these data strongly suggested that almost all of the interferon released by lung mononuclear cells was IFNy.
Spontaneous release of IFNy by lung mononuclear cells from patients with pulmonary sarcoidosis. In contrast to normal lung mononuclear cells, the mononuclear cells recovered from the lungs of patients with pulmonary sarcoidosis were spontaneously releasing considerable amounts of interferon (Fig. 1  A) . Like the interferon released by normal lung mononuclear cells, the interferon released by sarcoid cells was also predominantly IFN-y (Table I) (Fig. 1 B) . Interestingly, while most of the patients studied had sarcoidosis confined to the lung, these two individuals also had active sarcoidosis manifest in several organs including the eyes, skin, liver, spleen, and central nervous system. The IFNy spontaneously released by lung mononuclear cells of sarcoid patients was being released by both T lymphocytes and alveolar macrophages (Fig. 2) . The (Fig. 3) . In contrast, alveolar macrophages from patients with sarcoidosis appeared to be activated in that they demonstrated enhanced spontaneous tumor cytotoxicity. This was true for sarcoid patients with inactive disease (P < 0.05, sarcoid compared to normals) and sarcoid patients with active disease (P < 0.02, sarcoid compared to normals). Further, the level of spontaneous tumor cytotoxicity was greater for the sarcoid patients with active disease than those with inactive disease (P < 0.01). However, when alveolar macrophages from sarcoidosis patients with inactive disease were incubated with IFNy before addition of target cells, enhanced tumor cytotoxicity was observed (P < 0.001, compared to alveolar macrophages cultured in medium alone before the addition of target cells). The resultant level of activation produced by the addition of IFNy to the cultures was similar to that seen in sarcoidosis patients with active disease (P > 0.1). Similar enhancement of alveolar macrophage activity in these patients was observed after culture with lipopolysaccharide (P < 0.001, data not shown).
Effect ofcorticosteroid therapy on spontaneous IFNy release by sarcoidosis lung mononuclear cells. Sequential studies of sarcoidosis patients who received no therapy demonstrated no significant alteration in the level of IFNy spontaneously released by their lung mononuclear cells (P > 0.4, Fig. 4 A) . In contrast, almost all patients treated with corticosteroids exhibited a marked decrease in spontaneous IFNy production (P < 0.02, Fig. 4 B) .
Discussion
Gamma interferon is a mediator that lymphocytes and mononuclear phagocytes utilize to up-regulate immune and inflammatory processes. The present study demonstrates that in active pulmonary sarcoidosis, a disorder characterized by a variety of exaggerated immune and inflammatory processes localized to the lung, lung T lymphocytes and alveolar macrophages are spontaneously releasing large amounts of this mediator. When these patients are treated with corticosteroids, a therapy known to suppress the disease process, IFNy release by lung mononuclear cells is also suppressed. At least one role for IFNy in this disorder may be to activate alveolar macrophages, since the alveolar macrophages from sarcoid patients with active disease exhibit a high level of spontaneous tumoricidal activity, and IFNy enhances the tumoricidal activity of alveolar macrophages of patients with inactive disease. Release of IFNy by lung mononuclear cells. Consistent with the concept that the human lower respiratory tract possesses a competent immune system, lung mononuclear cells have the capacity to release interferon when triggered with an appropriate stimulus. As with blood mononuclear cells, this interferon is primarily IFNy. These observations are consistent with the knowledge that, although these lung cells can mount an appropriate response when stimulated, they are normally relatively quiescent even though the lung must handle a relatively large burden of immune and inflammatory stimuli in its role as the organ of gas exchange (1 1).
Release ofIFN-y by sarcoidosis lung mononuclear cells. In contrast to lung mononuclear cells from normals, those from sarcoidosis patients spontaneously released considerable amounts of IFNy. Furthermore, this process was compartmentalized in that it was observed in almost all cases in lung, but not blood, mononuclear cells. Further, IFNy could not be detected in either plasma or the epithelial lining fluid of the lower respiratory tract, which suggests: it is not being released systemically in large quantities; and that even at the site of its release (i.e., the lower respiratory tract) it is being used on a local level in the immediate milieu of the cells releasing it.
While the majority of patients with sarcoid had lung mononuclear cells that were releasing IFNy, those from patients with active disease released approximately fourfold more than those from patients with inactive disease. Because (31) .
Spontaneous IFNy release has also been noted for blood mononuclear cells from patients with Behcets disease (36) and one patient with chronic lymphocytic leukemia (37) , and for T cells from one patient with a T cell lymphoma (38) . In contrast, human disorders have also been described in which there has been defective IFNy production by blood mononuclear cells after stimulation, including systemic lupus erythematosis (39), leprosy (40), acquired immune deficiency syndrome (41), IgA deficiency (42) , and retinitis pigmentosa (43 (46) . Against this hypothesis is the knowledge that viral infections are often associated with detectable interferon in serum (47, 48) , whereas no interferon can be detected in the serum of sarcoid patients. Further, viral infection of cells generally induces the release of nongamma interferons (1), whereas sarcoid lung mononuclear cells release almost exclusively IFNy.
Second, IFNy is released spontaneously by human bone marrow T cells infected with the human T cell lymphoma virus (HTLV-1) and T cells from patients with T cell lymphomas thought to be caused by HTLV-1 (49) . Since HTLV-l is a retrovirus in which DNA complementary to the viral genome is inserted into the human genome, these observations lead to the obvious speculation that sarcoid is associated with HTLV-1 infection. However, direct evaluation of lung T cells and serum from patients with active sarcoid has not demonstrated any signs of active or prior HTLV-l infection (50, 5 1) .
Third, while the extent of T cell proliferation accompanying antigen presentation by normal alveolar macrophages to autologous T lymphocytes is relatively limited, in sarcoid, T cell proliferation induced by antigen-presenting alveolar macrophages is enhanced approximately twofold (17) Role of corticosteroid therapy in treating pulmonary sarcoidosis. Although the long-term effectiveness of corticosteroids in the therapy of pulmonary sarcoidosis is controversial, there is no question that in the short term, corticosteroids clearly suppress the disease (11) . Consistent with this knowledge, and with the concept that IFNy plays a fundamental role in the pathogenesis of this disorder, treatment of sarcoid patients with corticosteroids caused a marked suppression of the spontaneous release of IFNy by lung mononuclear cells. These observations are also consistent with in vitro studies, which demonstrates that corticosteroids suppress the release of IFNy by mononuclear cells (62) , and with the in vitro studies that corticosteroids suppress the expression of IFNy mRNA by mitogen-stimulated mononuclear cells (63) .
Together, these studies suggest that release of IFNy by lung mononuclear cells may be a step in the pathogenic process of pulmonary sarcoid that is vulnerable to therapeutic attack. In this context, the release of IFN-y by lung mononuclear cells may not only be a useful monitor of disease activity, but also a useful monitor of the minimal dose of corticosteroids necessary to suppress the exaggerated inflammatory and immune process that characterizes this disorder.
